跳至主要内容
临床试验/NCT00830713
NCT00830713已完成3 期

Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo

Henry Ford Health System2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2009年1月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
40
试验地点
2
主要终点
effectiveness of MKTP in treating vitiligo

研究概览

简要总结

In vitiligo, the melanocytes are lost from the skin in certain areas. One treatment for vitiligo takes the melanocytes from areas of normal skin and places them on areas of that same person's body which have lost their color. This is called the melanocyte-keratinocyte transplantation procedure (MKTP). This procedure has been used successfully in over 3000 cases in India and Saudi Arabia. The purpose of this study is to see if it is effective when performed at the investigators' institution.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Be at least 18 years old
  • Have a diagnosis of vitiligo with no news lesions or growth of old lesions in the past 6 months
  • Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
  • Agree to follow and undergo all study-related procedures

排除标准

  • Female patients who are breastfeeding, pregnant, or planning to become pregnant
  • Patients with a history of developing vitiligo or keloids at sites of trauma
  • Patients self-reported as having HIV or Hepatitis C
  • Patients self-reported as having uncontrolled Diabetes Mellitus
  • The investigator feels the patient should not participate in the study for any reason

结局指标

主要结局

effectiveness of MKTP in treating vitiligo

时间窗: 6 months

Assessed by percent repigmentation (excellent= 100%-95%, good= 94%-65%, fair= 64%-25%, poor= 24%-0%).

次要结局

  • safety of MKTP in treating vitiligo(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Iltefat Hamzavi

Dermatologist

Henry Ford Health System

研究点 (2)

Loading locations...

相似试验